Get the Stockscreener App
84.85
5.25%
-4.70
Ptc Therapeutics Inc stock is traded at $84.85, with a volume of 1.05M.
It is down -5.25% in the last 24 hours and up +15.68% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
See More
Previous Close:
$89.55
Open:
$89.71
24h Volume:
1.05M
Relative Volume:
0.60
Market Cap:
$7.04B
Revenue:
$1.73B
Net Income/Loss:
$682.64M
P/E Ratio:
10.97
EPS:
7.7364
Net Cash Flow:
$411.18M
1W Performance:
+1.85%
1M Performance:
+15.68%
6M Performance:
+9.44%
1Y Performance:
+71.34%
1-Day Range:
$83.83
$89.71
1-Week Range:
$82.70
$90.87
52-Week Range:
$43.17
$90.87
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
84.85 | 7.04B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Dec-01-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-17-25 | Initiated | Truist | Buy |
| May-09-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-07-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-07-25 | Initiated | Scotiabank | Sector Perform |
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
PTC Therapeutics (PTCT) Q3 2024 earnings summary - Quartr
PTC Therapeutics (PTCT) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
PTC Therapeutics (PTCT) Q2 2024 earnings summary - Quartr
PTC Therapeutics (PTCT) Stock May Be Fully Priced After Rare Disease Data - Yahoo Finance
Reasons why investors should consider betting on PTC stock now - MSN
Is PTC Therapeutics (PTCT) A Bargain Following Its Russell 2000 Defensive Index Additions? - Yahoo Finance UK
PTC Therapeutics Drops 5.5% Amid Sector-Wide Selling - AlphaStreet
Reasons Why Investors Should Consider Betting on PTC Stock Now - Yahoo Finance
PTCT (NASDAQ: PTCT) affiliate sale notice — Form 144 - Stock Titan
Form 144 PTC THERAPEUTICS For: 9 July By Investing.com - Investing.com Australia
Stocks Look Shaky, But This Sector is Booming (Biotech) - Yahoo Finance
[144] PTC THERAPEUTICS, INC. SEC Filing - Stock Titan
Responsive Playbooks and the PTCT Inflection - Stock Traders Daily
Ptc therapeutics tech ops chief sells $4.1m in common stock By Investing.com - Investing.com India
Form 4 PTC Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
PTC Therapeutics Inc. (PTCT) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120 - Moomoo
PTC Therapeutics(PTCT.US) Officer Sells US$4.09 Million in Common Stock - Moomoo
Ptc therapeutics tech ops chief sells $4.1m in common stock - Investing.com
PTC Therapeutics’ Mark Boulding, exec VP, sells $432,117 in stock - Investing.com
PTC Therapeutics’ Mark Boulding, exec VP, sells $432,117 in stock By Investing.com - Investing.com Canada
PTC Therapeutics (PTCT) officer sells shares after exercising options - Stock Titan
PTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance Australia
PTC Therapeutics Jumps 5.1% Amid Sector-Wide Rally - AlphaStreet
Form 144 PTC THERAPEUTICS For: 7 July By Investing.com - Investing.com Nigeria
PTCT (NASDAQ: PTCT) — 24,613 shares reported for sale after option exercise - Stock Titan
PTCT Maintains Rating by RBC Capital -- Price Target Raised to $85 - GuruFocus
Ptc Therapeutics stock hits all-time high of 87.56 USD - Investing.com
Ptc Therapeutics stock hits all-time high of 87.56 USD By Investing.com - Investing.com Canada
PTC Therapeutics weighs strategy amid rare disease focus - Ad-hoc-news.de
RBC Capital Adjusts PTC Therapeutics Price Target to $85 From $82, Maintains Sector Perform Rating - Moomoo
Does Triple Russell 2000 Defensive Index Inclusion Reframe PTC Therapeutics’ Risk Profile And Rare-Disease Story (PTCT)? - simplywall.st
Form 144 PTC THERAPEUTICS For: 6 July By Investing.com - Investing.com South Africa
PTCT (NASDAQ) insider sales: 50,162 shares in June; option exercise 07/06/2026 - Stock Titan
PTCT (NASDAQ) affiliate plans option exercise; director sold 10,522 shares - Stock Titan
All eyes on PTC Therapeutics earnings after brutal Q4 miss - Investing.com
Enterprise value to EBIT forward of PTC Therapeutics, Inc. – NASDAQ:PTCT - TradingView
PTC Therapeutics updates investors on rare disease pipeline as Nasdaq-listed biotech advances progra - AD HOC NEWS
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data - TradingView
PTC Therapeutics Inc (PTCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ptc therapeutics chief technical ops officer sells $693k in stock By Investing.com - Investing.com Australia
Ptc therapeutics chief technical ops officer sells $693k in stock - Investing.com Australia
Form 4 PTC Therapeutics Inc For: 30 June By Investing.com - Investing.com South Africa
Enterprise value to EBITDA forward of PTC Therapeutics, Inc. – NASDAQ:PTCT - TradingView
Price to sales forward of PTC Therapeutics, Inc. – NASDAQ:PTCT - TradingView
Enterprise value to revenue forward of PTC Therapeutics, Inc. – NASDAQ:PTCT - TradingView
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to Russell 2000 Value-Defensive Index - marketscreener.com
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Price to earnings forward of PTC Therapeutics, Inc. – HAM:BH3 - TradingView
Price to earnings forward of PTC Therapeutics, Inc. – FWB:BH3 - TradingView
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to Russell 2000 Defensive Index - marketscreener.com
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):